Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | ALPL | P05186 | 2/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10153817 | 0.82 | SMN1; SMN2 (0.48) | CCR2LMNAALDH1A1SGK1 | |
| SCHEMBL2372705 | 0.82 | MCL1 (0.62) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1790814 | 0.81 | CNR1 (0.51) | ALPLACLYCCR2CNR1MCL1 | |
| SCHEMBL11512517 | 0.81 | MCL1 (0.61) | CA12CA1CA2CA3CA4 | |
| SCHEMBL11512510 | 0.81 | MCL1 (0.61) | CA12CA1CA2CA3CA4 | |
| SCHEMBL26413808 | 0.81 | GAA (0.48) | HPGDTSHRLMNAALDH1A1SGK1 | |
| SCHEMBL1805587 | 0.79 | ALOX5AP (0.41) | CA12CA1CA2CA3CA4 | |
| SCHEMBL6130536 | 0.79 | CA12 (0.50) | CA12CA1CA2CA3CA4 | |
| SCHEMBL31429890 | 0.79 | MAPT (0.45) | CA12CA1CA2CA3CA4 | |
| SCHEMBL6835906 | 0.79 | P2RX1 (0.54) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | XBP1, ERN1, ERN2 | CA12 4857/4885CA1 4671/4885CA2 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.